Compare MYE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYE | SLN |
|---|---|---|
| Founded | 1933 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1995 | 2010 |
| Metric | MYE | SLN |
|---|---|---|
| Price | $29.84 | $19.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 241.9K | ★ 4.3M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ 389.47 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | ★ $559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.49 | $131.31 |
| P/E Ratio | $65.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.66 | $4.19 |
| 52 Week High | $37.45 | $19.87 |
| Indicator | MYE | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 79.05 |
| Support Level | $20.39 | $4.66 |
| Resistance Level | $32.10 | N/A |
| Average True Range (ATR) | 1.14 | 0.24 |
| MACD | -0.13 | 0.64 |
| Stochastic Oscillator | 42.03 | 99.06 |
Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.